Sector News

Astellas names James Robinson President, Americas Operations

February 8, 2016
Life sciences

/PRNewswire/ – Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka today announced the promotion of James Robinson as president, Americas Operations, for Astellas US LLC, with responsibility for the company’s operations in North and South America, effective April 1, 2016. Robinson previously served as president, Astellas Pharma US, representing the commercial organization in the United States — a role he assumed in 2013.

Robinson will succeed Masao Yoshida, who is retiring in June 2016.

“As a 10-year veteran of Astellas with more than 20 years of healthcare industry experience, Jim’s commitment to operational and commercial excellence has helped Astellas grow dramatically in the Americas,” said Hatanaka. “His deep experience, skills and strong commitment to operating and leading with the highest sense of ethics and compliance will help Astellas stay focused on our global vision to be on the forefront of healthcare change to turn innovative science into value for patients.”

“Astellas is respected for its unwavering focus on supporting patients. This foundational idea is our compass for continued growth in the Americas,” said Robinson. “We will remain committed to serving patients, pursuing operational excellence within the organization and building Astellas’ presence throughout the Americas.”

Robinson joined Astellas in 2005 as the vice president of health systems, responsible for managed markets, reimbursement strategy, state government affairs and government accounts, and has since held positions of increasing responsibility. In 2011, Robinson was named senior vice president, sales and marketing, leading the US organization responsible for sales, marketing, new product planning, market access and commercial operations.

Robinson began his career at Schering-Plough in 1992 as a sales representative, and held positions of increasing responsibility until he was promoted to vice president of hepatitis sales and managed care in 2003. In this position, he led the largest specialty pharmaceutical sales division within Schering-Plough until he joined Astellas.

He serves as chairman of the Pharmaceutical Research and Manufacturers of America State Committee, is a member of the BioScience council for ChicagoNEXT and serves on the board of directors of MATTER. He is member of The Commercial Club of Chicago and is a graduate of DePaul University.

Source: Astellas

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”